A Phase I evaluation of satri-cel, a claudin 18.2-targeted CAR T therapy, reported durable peritoneal disease control in three advanced gastric cancer patients with peritoneal metastases. All three patients had confirmed high claudin 18.2 expression and achieved verified clinical and radiologic benefit after infusion, with reported overall survival durations extending into the mid-multi-year range. The findings focus on local tissue activity: peripheral blood CAR T cell clearance dropped to near-undetectable levels by about day 30 in the trial cohort, while peritoneal control persisted. In one case, satri-cel enabled conversion surgery eight months after treatment, with no further peritoneal progression reported post-resection. For a disease setting where outcomes remain poor and peritoneal spread options are limited, the report provides early clinical proof-of-concept that claudin 18.2 CAR T can deliver meaningful compartment-specific activity.
Get the Daily Brief